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ABSTRACT 
    Central retinal vein occlusion (CRVO) is a retinal vascular disorder that may cause severe 
visual impairment. When CRVO occurs the venous blood flow is impeded with elevated 
intraluminal pressure upstream to the occlusion. The increased hydrostatic pressure causes 
extravasation of fluid to the extracellular space that compromises arterial perfusion inducing 
retinal hypoxia. This will release vascular endothelial growth factor (VEGF) and 
inflammatory mediators that in turn induce macular edema (ME) and ocular 
neovascularization. A seasonal variation in cardiovascular disease onset has been shown 
previously with a higher incidence during the winter season than in the summer. Serum 
vitamin D levels are known to have a significant seasonal variation with a peak occurring in 
the summer.  A few studies have suggested a seasonal onset of CRVO with more cases 
presenting during winter, but no study has investigated vitamin D levels in these patients. 
     In paper I we studied prospectively if repeated intravitreal bevacizumab (IVB) injections 
every 6 weeks for 6 months could improve visual acuity as compared to sham-treated control 
patients with ME secondary to CRVO. After 24 weeks 18/30 (60.0%) patients in the study 
group had gained ≥15 letters compared with 6/30 (20.0%) patients in the control group 
(p=0.003). At the end of follow up patients in the study group improved 14.1 letters 
compared to a loss of 2.0 letters in the control group (p<0.01). We showed for the first time in 
a randomized prospective study the superiority of IVB treatment compared to sham injections 
in CRVO. 
     In paper II both groups received treatment with 4 IVB injections every 6 weeks for 6 
months. The objectives were to investigate if this regime could maintain visual acuity and to 
elucidate the impact of delaying treatment for 6 months in patients with ME secondary to 
CRVO. In the original IVB group a further gain of 2.0 letters was seen with the fixed 
injection schedule during week 24 to 48. The original sham group, improved to a vision gain 
of 4.6 letters at week 48 (p<0.05). Disease duration seemed to have a critical impact on visual 
outcome. Patients initially on a sham-regime in paper I improved with IVB treatment after 24 
weeks but significantly less than the original IVB group. 
     In paper III we investigated retrospectively the seasonality in CRVO onset and the yearly 
incidence of CRVO in Stockholm, Sweden. Every year during the 6 year study the highest 
CRVO onset occurred during the winter-spring period and was significantly higher than 
during the other seasons reaching its lowest levels in autumn. We found that the CRVO 
incidence was 2/10000 for persons aged over 40 years. The annual incidence increased from 
0.25/10000 at 45 years of age up to 7/10000 above 80 years of age.  
     In paper IV we tested prospectively the hypothesis that patients with CRVO had an 
increased risk of vitamin D deficiency compared to matched controls. We found that more 
than 50% of the patients with CRVO had deficient vitamin D levels. In the complete data set 
no significant differences in vitamin D levels were found between the study groups.  Patients 
less than 75 years old had significantly lower vitamin D levels compared to controls.   
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1 CRVO - INTRODUCTION 
 
Retinal vein occlusion (RVO) is a common retinal vascular disorder that may cause severe 
visual impairment. RVO is classified according to the location of the occlusion. In branch 
retinal vein occlusion (BRVO) a branch of the retinal venous tree is occluded. In central 
retinal vein occlusion (CRVO) there is a central retinal vein obstruction in the optic nerve. A 
hemicentral retinal vein occlusion (HCRVO) occurs when of 1 of the 2 trunks of the central 
retinal vein in the optic nerve is occluded (see anatomy below). A HCRVO could be 
considered as a variant of CRVO. There are other anatomic subtypes of RVO.  A hemispheric 
retinal vein occlusion is a BRVO with an occlusion at the arteriovenous crossing on or near 
the optic disk that affects the upper or the lower part of the retina (Hayreh 2012). This occurs 
when the venous return from approximately one-half of the retina is affected while small 
occlusions affecting only the posterior pole are described as macular retinal vein occlusion. 
 
1.1. ANATOMY 
 
In the embryogenesis of the eye, two trunks of the central retinal vein (CRV) lie on either 
side of the central retinal artery (Mann, 1969). After birth usually one of the trunks disappears 
leaving a single central trunk (figure 1). In approximately 20% of eyes both trunks persists 
(Chodpar 1986) (figure 2). Occlusion of one of those two trunks results in the development of 
HCRVO. The CRV which receives blood from the retina runs through the optic nerve and 
after a short distance it drains blood usually into the superior ophthalmic vein and further into 
the cavernous sinus (Cheung 2003). During its course in the optic nerve numerous collaterals 
exist with the choroidal circulation (figure 1). A considerable variability has been described 
in the venous orbital drainage with many collaterals and anatomic variants. The CRV may 
sometimes join the inferior ophthalmic vein, or even the cavernous sinus directly (Hayreh 
2006). Hence differences in the venous orbital anatomy can cause various clinical pictures. 
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      Figure 1. Normal anatomy                               Figure 2. Two central retinal vein trunks 
CRA = central retinal artery, CRV = central retinal vein, LC = lamina cribrosa, ON = optic 
nerve; R = retina, S = sclera, Col. Br = collateral branches (Hayreh 2014) 
 
1.2. PATHOGENESIS  
 
Degenerative changes of the vessel wall, venous stasis, and blood hypercoagulability may 
increase the risk of thrombosis (Virchow´s triad). The pathogenesis of CRVO is believed to 
be associated with arterial disease. The central retinal vein and artery share a common 
adventitial sheath.  Arterial wall changes due to hypertension or atherosclerosis transform the 
artery into a rigid structure that impinges upon the pliable CRV. The flow through the narrow 
segment of vein within the lamina cribrosa (figure 1, black arrow) becomes turbulent which 
may damage the endothelium. This can contribute to stasis, thrombosis, and occlusion (Green 
1981). The concept that the occlusion is located at the lamina cribrosa is mainly based on the 
landmark histopathological studies by Green in eyes with severe ischemic CRVO. It has been 
argued that in some cases the occlusion may be farther back (figure 1, red arrow) and not at 
the lamina cribrosa. This could contribute to a milder retinopathy because of the abundant 
collateral venous outflow in the optic nerve (Hayreh 1994). 
     When CRVO occurs the venous blood flow is impeded causing an elevated intraluminal 
pressure upstream to the occlusion. The increased hydrostatic pressure causes extravasation 
of fluid to the extracellular space, the development of retinal hemorrhage and may 
compromise arterial perfusion resulting in variable amounts of capillary occlusion. The 
hypoxia stimulates the release of cytokines, vascular endothelial growth factor (VEGF) and 
other inflammatory mediators. This may disrupt the blood-retina barrier causing further 
extravasation of fluid and hemorrhages (Kaur 2008). The effect of VEGF in the pathogenesis 
of CRVO will be discussed in detail later.  
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1.3. ETIOLOGY  
 
A basic risk factor for CRVO is advancing age. Systemic hypertension and hyperlipidemia 
are the strongest risk factors associated with the disease (O’Mahoney 2008). There is also a 
higher risk of CRVO in patients with ocular hypertension and glaucoma (The Eye Disease 
Case-Control Study Group 1996). It has been argued that venous stasis induced by the raised 
intraocular pressure may contribute to the occlusion (Hayreh 2004). A low ocular perfusion 
pressure (calculated as two-thirds of mean arterial pressure minus intra ocular pressure) has 
also been associated with an increased risk of CRVO. Other significant risk factors are 
cardiovascular disease and diabetes (Kolar 2014).  In young patients coagulopathy and 
thrombophilia should be considered in the etiology (Yau 2008). Knowledge on thrombophilic 
abnormalities in CRVO is often based on small retrospective studies and case reports with 
conflicting results. Increased risk of CRVO has been associated with deficiency of protein C 
(Tekeli 1999), protein S (Yap 2007) and antithrombin III (Ririe 1979). Furthermore other 
studies have reported that factor V Leiden mutation (Rehak 2008) , antiphospholipid 
(Agarwal 2009) and anticardiolipin syndrome (Glueck 2012) hyperhomocysteinaemia (Cahill 
2003) and  elevated levels of  plasminogen activator inhibitor-1 (Marcucci 2001) may play a 
role in the etiology of CRVO. 
     Several other studies have failed to prove this relationship. In a case-controlled study no 
association was found between antithrombin, Protein C, Protein S and homocysteine levels, 
lupus anticoagulant and anticardiolipin antibodies and risk of CRVO (Di Capua 2010). 
 
1.4. EPIDEMIOLOGY 
 
Studies have found prevalence rates of CRVO ranging from 0.08-0.2% (Mitchell 1996, Klein 
2000, Yasuda 2010). The Beaver Dam Eye Study reported a 15-year cumulative CRVO 
incidence of 0.5%. Arakawa reported a 9-year cumulative CRVO incidence of 0.3% 
(Arakawa 2011). 
 
1.5. CLINICAL PICTURE 
 
Patients usually present with a sudden unilateral blurred vision. The retinal veins are tortuous 
and dilated. Dot/blot and flame-shaped hemorrhages, throughout all four quadrants out in the 
periphery are seen. Optic disc and macular edema (ME) are usually present. Soft exudates as 
a sign of retinal ischemia may be present (figure 3). Classically CRVO is divided into 
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ischemic and non-ischemic types (Hayreh 1983). The disease is classified as non-ischemic 
when less than 10 disc areas of non-perfusion are seen as assessed by fluorescein 
angiography (FA) and ischemic with more than 10 disc areas of non-perfusion (The Central 
Vein Occlusion Study Group 1995). With standard FA mainly the posterior portion of the eye 
is visualized and large portions of ischemia in the peripheral retina may be missed. Recent 
technological advances have made high-resolution peripheral angiographic visualization 
possible. Ultra wide field FA with the Optos C200 MA scanning laser ophthalmoscope 
(Optos PLC, Dunfermline, United Kingdom), provides visualization up to 200° peripherally 
(Friberg 2008). This can contribute to a more adequate evaluation of the degree of ischemia. 
A recent report investigated the peripheral ischemia in patients with non-ischemic CRVO 
(classified with standard FA visualization). When evaluated with Optos- FA all eyes had 
significant peripheral ischemia averaging 92 disc areas of non-perfusion (Spaide 2011). 
Hence the assumption that findings in the posterior portion of the eye are representative of the 
whole eye can be erroneous and the concept of 10 disc areas of non-perfusion is probably 
insufficient. Patient classified as non-ischemic with standard FA may have extensive 
peripheral ischemia. Extensive hemorrhages at presentation may make angiographic 
evaluation impossible. Functional tests such as visual acuity, relative afferent pupillary defect 
(RAPD), visual fields and electroretinography may help in differentiating the types of CRVO 
(Hayreh 1990).  Non-ischemic CRVO is the most common form accounting for 
approximately 80% of cases (Hayreh 1994). Patients usually present with mild to moderate 
visual loss, commonly 20/200 or better, and an absent RAPD. Non-ischemic CRVO may in a 
few cases resolve fully with good visual outcome. However frequently it results in 
significant, permanent visual loss and may progress to the ischemic type (Chen 1995). Eyes 
with ischemic CRVO present with severe visual loss, extensive retinal hemorrhages, soft 
exudates and presence of a RAPD (figure 3). Commonly there is extensive macular ischemia 
contributing to a poor visual prognosis. 
1.5.1 Natural course 
Resolution of the retinopathy often takes a long time and is in most cases associated with 
substantial vison loss. One year after disease onset 30 % of non-ischemic CRVO cases have 
resolved while only 6 % of the ischemic cases show no retinopathy (Hayreh 2015). The 
mechanism by which CRVO resolves is complex and not completely understood. 
Recanalization of the thrombus occurs commonly during the first year of disease but involves 
in most cases only a minor part of the lumen (Green 1981). Compensatory collaterals that 
bypass the occlusion may contribute to the resolution of the disease. Collateral vessels shunt 
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venous blood from the retinal circulation to the choroidal vasculature thus improving the 
venous retinal blood flow. The site of occlusion determines how efficient the collateral 
outflow can be.  Occlusions located downstream to the lamina cribrosa have an abundancy of 
vessels that can develop into prominent collaterals while occlusions at the lamina cribrosa 
only have a few vessels from the prelaminal region that can develop into retinociliary shunts. 
These retinociliary collaterals are seen at the optic disc on clinical examination, while deeper 
collaterals in the optic nerve cannot be observed. The appearance of retinociliary vessels is 
not necessarily an indicator of a good prognosis since occlusions closer to the lamina cribrosa 
are associated with a more severe retinopathy. It has been shown that eyes with non-ischemic 
CRVO that developed retinociliary shunt vessels had a slower resolution of macular edema 
and a worse visual outcome (Hayreh 2011). 
 
   
Figure 3.  Left: Fundus photograph of CRVO showing torturous veins with extensive 
hemorrhages and soft exudates. Right: Fundus angiogram with severe retinal ischemia. 
 
1.6. VEGF IN CRVO 
 
In humans the different VEGF molecules include, VEGF-A, VEGF-B, VEGF-C, VEGF-D 
and placenta growth factor (PlGF) (Holmes 2007). The retinal hypoxia in CRVO causes the 
release of VEGF-A and inflammatory mediators. This can induce ME and ocular 
neovascularization. 
     ME is the most common cause of visual impairment in CRVO (McIntosh 2010). When the 
retina becomes hypoxic the cells produce hypoxia-inducible factor (HIF). HIF stimulates the 
production of VEGF-A that in turn binds to VEGF receptors (VEGFR-1 and -2) on the 
endothelial cells. VEGFR-2 regulates vascular endothelial function and mediates most of the 
cellular response to VEGF-A (Holmes 2007). VEGFR-2 is a tyrosine kinase receptor that is 
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activated by transphosphorylation. This activates a cellular signaling pathway that ultimately 
causes the phosphorylation of the intracellular tail of vascular endothelial (VE)-cadherin 
(Gavard 2006). VE-cadherin plays an important role in cell to cell adhesion at the adherens 
junctions and protects the integrity of the endothelial barrier. The phosphorylation causes 
endocytosis and internalization of VE-cadherin, thereby disrupting the endothelial barrier and 
promoting macular edema by allowing passage of macromolecules and fluid. Contraction of 
the endothelial actin/myosin cytoskeleton also plays a part in the pathogenesis of ME.  
Myosin phosphorylation creates a contractile force that pulls VE-cadherin inward, forcing 
dissociation of the adherens junction thereby producing interendothelial gaps 
(Vandenbroucke 2008) (figure 4). The pathways by which VEGF-A can cause ME are not 
fully understood and there may be other important mechanisms involved.   
 
                  
Figure 4. VEGF-induced disruption of cell−cell adhesion. VEGF-A binding to VEGFR-2 
activates an intercellular signaling pathway causing the phosphorylation of VE-cadherin and 
the actin/myosin complex promoting endocytosis and internalization of VE-cadherin. 
(Adapted by D Epstein from figure courtesy A Kvanta) 
 
Ocular neovascularization is usually only seen in ischemic CRVO and is most common in the 
anterior part of the eye causing iris rubeosis and neovascular glaucoma. Anterior segment 
neovascularization typically occurs within 1-4 months and virtually all cases occur within 1 
year (Hayreh 1983). Neovasculariztion of the iris (NVI) and the angle (NVA) can cause the 
development of fibrovascular tissue and subsequently anterior synechiae obstructing aqueous 
outflow through the trabecular meshwork resulting in neovascular glaucoma. Early treatment 
of the ischemic retina with panretinal photocoagulation (PRP) is important in order to reduce 
the VEGF- induced angiogenesis and possibly avoid the anterior synechiae formation 
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(Browning 2012). Adjuvant anti-VEGF therapy could be a useful tool to efficiently reduce 
the VEGF load before the effect of the PRP treatment is seen (Wakabayashi 2008, Lüke 
2013). Neovascularization of the posterior segment is uncommon and typically occurs later 
than development of iris rubeosis with an average time until onset up to 12 months (Murdoch 
1991). Histopathological evaluation of eyes with CRVO has shown an absence of retinal 
capillary endothelial cells possibly complicating the process of retinal angiogenesis (Little 
1979).  Neovascularization of the optic disc (NVD) is seen more often than 
neovascularization of the retina (NVE). Vitreous hemorrhage (VH) may be caused by NVD 
and NVE but is more commonly due to a break-through bleeding from the hemorrhagic retina 
especially when occurring in the early stages of the disease when retinal neovascularization is 
uncommon (Hayreh 2015). Thus, the occurrence of VH does not necessarily indicate retinal 
neovascularization. Several studies have shown that patients with a posterior vitreous 
detachment (PVD) of the vitreous have a much lower risk of retinal neovascularization 
(Akiba 1991, Hikichi 1995). It has been argued that the vitreous serves as a scaffold 
necessary for the development of the retinal neovascularization (Browning 2012). It has been 
suggested that a PVD may share physiological features with a vitrectomized eye (Stefánsson 
2009). Several studies have shown that the retinal oxygenation improves after vitrectomy 
(Stefánsson 1990, Williamson 2009) and this process may also occur after a PVD. As a result 
of the improved retinal oxygenation the VEGF production is reduced. Additionally VEGF 
may be cleared better into the vitreous cavity after vitrectomy or PVD reducing the preretinal 
VEGF concentration and risk for ischemic complications (Stefánsson 2009). 
 
1.7. TREATMENT OF MACULAR EDEMA 
 
The last decade has witnessed a revolution in the treatment of ME. Potent anti-VEGF drugs 
and corticosteroids have dramatically improved the visual outcomes.  
     Anti-VEGF treatment: Intravitreal treatment with ranibizumab, aflibercept and 
bevacizumab have all shown superiority to the natural history of the disease. Intravitreal 
injections can be given monthly due to the relative long intravitreal half-life (t½) of anti-
VEGF drugs. Bevacizumab, ranibizumab and aflibercept have a t½ of between 7-10 days 
(Meyer 2011, Krohne 2012 and Stewart 2014). 
     Ranibizumab: Ranibizumab (Lucentis®, Genetech Inc.) is a monoclonal antibody Fab 
fragment (48kDa) that by binding to VEGF-A prevents the interaction of VEGF-A with its 
receptors on the surface of endothelial cells. It is FDA approved for treating age- related 
macular degeneration, pathologic myopia, diabetic ME and ME secondary to RVO. Best 
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corrected visual acuity (BCVA) is measured with an ETDRS (Early treatment diabetic 
retinopathy study) chart where every line represents 5 letters. The CRUISE study evaluated 
monthly treatment with ranibizumab versus sham injections in patients with CRVO. After 6 
months patients the ranibizumab group had gained a mean of 14.9 letters, compared with 0.8 
letters in the sham group (Brown 2010). The visual gain was maintained after 12 months 
when treated on a pro renata regimen (PRN) improving 13.9 letters compared to baseline. 
The sham group received active treatment after 6 months improving 7.3 letters (Campochiaro 
2011). Concomitant with the rapid improvement in visual acuity there was a fast reduction of 
the ME.  The central retinal thickness (CRT) decreased 452 µm compared to 168µm in the 
sham arm.  
     Aflibercept: Aflibercept (Eylea®, Bayer HealthCare Pharmaceuticals) is a recombinant 
fusion protein (97kDa) consisting of VEGF-binding portions from the extracellular domains 
of human VEGFR-1 and -2, fused to the Fc portion of the human IgG1 immunoglobulin. 
Aflibercept binds to circulating VEGFs thereby inhibiting the activity of the VEGF subtypes 
VEGF-A and VEGF-B, as well as to PlGF. It is FDA approved for treating age-related 
macular degeneration, diabetic ME and ME secondary to RVO. The COPERNICUS study 
investigated the treatment of monthly aflibercept injections compared to sham in CRVO. 
After 6 months patients the aflibercept group had gained a mean of 17.3 letters, compared 
with a loss of 4.0 letters in the sham group. The CRT decreased 457 µm compared to 145µm 
in the sham arm. No patients in the aflibercept arm developed neovascularization versus 7% 
in the sham group (Boyer 2012). The visual gain was maintained with PRN treatment at 12 
months. The aflibercept group improved 16.2 letters compared to a 3.8 letter gain in the 
previous sham group (Brown 2013).  
     Bevacizumab: Bevacizumab (Avastin®, Genetech Inc.) is a recombinant humanized 
monoclonal antibody (149kDa) that inhibits VEGF-A. It has a similar mode of action as 
ranibizumab (see above). It was originally developed as a drug for various metastatic cancers. 
It has also gained extensive off-label use in treating various eye diseases especially age 
related macular degeneration and vascular retinopathies. When initiating this thesis in 2010 
no prospective randomized sham-controlled studies had been conducted in treating CRVO 
patients with bevacizumab. However several case series had shown good effect on visual 
acuity improvement and reduction of ME (Prager 2009, Figueroa 2010). 
     Corticosteroid treatment: Ozurdex® is a slow release dexamethasone implant that is given 
as an intravitreal injection. The implant achieves higher and more stable levels of 
dexamethasone than other routes of corticosteroid administration and has shown a peak 
intravitreal concentration at 60 days after administration. The intravitreal levels of the drug 
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then start to decline and at 90 days low concentrations are found (Chang-Lin 2011). The 
GENEVA study evaluated the treatment with Ozurdex® compared to sham injections in 
patients with ME due to RVO. After 60 days the study group improved 9.7 letters compared 
to a visual loss of 1.3 letters in the control group. After 90 and 180 days the study group 
improved 5.0 and 0.8 letters respectively compared to baseline (Haller 2010). After 6 months 
all patients received open label Ozurdex® treatment. After 60 days the study group improved 
8.0 letters compared to 4.0 letters in the control group. At 12 months 30% of the retreated 
phakic patients developed cataract. A third of the retreated patients had at least a 10-mmHg 
increase in intraocular pressure (IOP) from baseline at some point in the 12-month study but 
in virtually all cases the IOP was normal 180 days after the last treatment (Haller 2011). The 
results from the CRUISE, COPERNICUS and GENEVA studies suggest that early treatment 
is important in order to optimize the visual outcome in patients with CRVO. 
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2 SEASONALITY IN CARDIOVASCULAR DISEASE 
 
Cardiovascular disease (CVD) is the leading cause of death worldwide. In 2008 30% of all 
global deaths were caused by CVDs (Mendis 2011). A seasonal variation in CVD onset has 
been shown in several studies with a higher incidence during the winter season than in the 
summer. This relationship applies to both arterial disease and venous thromboembolism 
(VTE). Seasonal variations in the arterial blood pressure have been seen in many studies. 
Both systolic and diastolic blood pressures show a peak during the winter and a nadir in the 
summer (Fujiwara 1995, Minami 1996, Sinha 2010). Similarly seasonality has been 
described in numerous studies in the onset of aortic dissection (Lasica 2006), stroke (Khan 
1996), heart failure (Boulay 1999), myocardial infarction (Hopstock 2011), and heart 
arrhythmias (Frost 2002). In VTE a similar pattern is seen both in deep vein thrombosis and 
pulmonary embolism (Gallerani 2004, Manfredini 2004). A meta-analysis of the seasonal 
onset of VTE showed an increased risk of 14% in disease onset during the winter (Dentali 
2011). 
 
2.1. SEASONALITY IN CENTRAL RETINAL VEIN OCCLUSION  
 
The literature is relatively sparse in information regarding seasonality in CRVO. A large 
retrospective population-based study from Taiwan including over 20000 patients showed a 
significant seasonality with a peak in January (Ho 2008). Lavin et al found a more frequent 
disease onset in the period September to February (Lavin 1987). Other studies have failed to 
find a seasonal relationship (Malayan 1999). In a large study including more than 1000 
patients most patients had a disease onset between January and April, however this was not 
statistically significant (Hayreh 1992). No information is available on the seasonality in the 
Nordic countries. 
 
2.2. MECHANISMS - SEASONALITY 
 
The seasonality of CVDs could possibly be multifactorial. Suggested mechanisms include: 
 
2.2.1 Hypertension 
 
Raised systolic blood pressure is a significant risk factor for CVD and CRVO. Numerous 
studies have shown an increased blood pressure during the winter (Marti-Soler 2014). 
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Important mechanisms are peripheral vasoconstriction, decreased sweating and salt retention 
at colder temperatures (Cuspidi 2012). Several other risk factors for hypertension such as 
catecholamine, cholesterol and vasopressin have a seasonal variation with higher serum 
levels in the winter (Gordon 1988, Wittert 1992, Radke 2007). 
 
2.2.2 Temperature 
 
Both reduced indoor and outdoor temperature as recorded during winter have been shown to 
significantly increase blood pressure (Barnett 2007). Beside the direct effect on blood 
pressure an association has also been seen between cold temperature and increased blood 
viscosity. A cold environment may increase the platelet and the red blood cell counts, rise 
fibrinogen and cause a decrease in antithrombin III (Bull 1979, Keatinge 1984, Neild 1984). 
 
2.2.3 Air pollution 
 
Epidemiological studies have shown an increased risk for CVDs in relation to ambient 
particulate matter (PM) exposure. Higher PM concentrations have been observed during the 
winter months. Peters et al showed that elevated PM concentrations in the air may transiently 
increase the risk of MIs within 2 hours and 1 day after exposure (Peters 2001). 
 
2.2.4 Physical activity 
 
Physical inactivity is strongly correlated with CVD (Salo 2013). Physical activity is 
significantly higher in summer than in winter. It is believed that physical exercise improves 
the endothelial function (Black 2009). Exercise causes an increase in shear stress on the blood 
vessel endothelium. Blood vessels exposed to more shear stress are usually found to be free 
of atherosclerotic changes. Increased shear stress as a result of exercise may improve the 
endothelial function and can prevent CVD (Sherman 2000). 
 
2.2.5 Latitude 
 
The seasonality in CVD onset is affected by the distance from the Equator. In countries close 
to the Equator no significant seasonality in CVD presentation is seen while populations living 
in the northern or southern hemisphere show a significant seasonality (Marti-Soler 2014). 
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2.2.6 Vitamin D deficiency 
 
Serum vitamin D levels have a marked seasonal variation, with peaking serum levels in the 
summer and a nadir during winter (Brot 2001). Data from the Framingham Offspring Study 
suggested that hypertensive patients with deficient vitamin D levels had a 60% increased risk 
of a cardiovascular event compared to patients with better vitamin D status (Wang 2008). 
Two recent meta-analyses have demonstrated an association between 25(OH)-vitamin D 
deficiency with both hypertension (Burgaz 2011) and risk of CVD (Wang 2012). In type 2 
diabetes mellitus patients with low 25-OH vitamin D3 levels, supplementation with vitamin 
D reduced blood pressure and significantly increased blood vessel vasodilatation, a sign of 
improved endothelial function (Sugden 2008). Furthermore it has been shown that women 
with a more active sun exposure have a significantly lower risk of venous thromboembolism 
(Lindqvist 2009). 
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3 VITAMIN D - INTRODUCTION 
 
Vitamin D has long been known to regulate serum calcium and phosphate metabolism and 
promoting bone mineralization. During the last decades numerous publications have shown 
that vitamin D may also have an impact on several other physiological functions. Vitamin D 
deficiency has been associated with CVD, autoimmune diseases, type 2 diabetes mellitus, 
cancer and infectious diseases (Holick 2011). 
 
3.1. METABOLISM 
 
Vitamin D, the sunshine vitamin, is actually a hormone.  During exposure to ultraviolet B 
(UVB) irradiation in sunlight the 7-dehydrocholesterol in the skin is converted to previtamin 
D3. It is isomerized by the body heat to vitamin D3. In the liver it is hydroxylated by the 
vitamin D-25-hydroxylase to 25-hydroxyvitamin D3 (25(OH) D). This is the metabolite that 
is used to clinically measure vitamin D status. In order to become biologically active it is 
converted mainly in the kidneys by the 25-hydroxyvitamin D-1α-hydroxylase to its 
biologically active form 1,25-dihydroxyvitamin D3 (Holick 2011) (figure 5). 1,25-
dihydroxyvitamin D3 acts by binding to the vitamin D receptor (VDR), which is present in 
many cells throughout the body, including vascular smooth muscle cells (VSMC), 
endothelium and cardiomyocytes (Judd 2008). Normal levels of vitamin D have not been 
firmly established, but a level <50 nmol/l (20 ng/ml) is considered deficient and a threshold 
to avoid vitamin D deficiency associated complications (Ross 2011). 
 
 
                                              
         
Figure 5. Vitamin D synthesis (courtesy John Berardi, www.precisionnutrition.com) 
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3.2. FACTORS INFLUENCING VITAMIN D SYNTHESIS 
 
Vitamin D synthesis is dependent on the intensity of UVB irradiation which varies with 
season and latitude (Webb 1988). The solar zenith angle plays a crucial role in this process 
(figure 6). In the winter and at higher latitudes the zenith angle increases. The UVB 
irradiation has a longer path through the stratospheric ozone layer and less UVB light reach 
the earth’s surface (Holick 2007). In Nordic countries it is not possible to synthesize vitamin 
D at sufficient levels in winter and the exposure time required to reach a standard dose is 
impractical from at least September through April (Burgaz 2009, Webb 2006). Similarly 
during the morning and in the late afternoon, when the zenith angle is large, the incoming 
UVB light is not sufficient for vitamin D synthesis.  
 
  
Figure 6. Solar zenith angle (D Epstein)  
 
Skin pigmentation has also a major impact on the vitamin D synthesis. Melanin absorbs 
efficiently the UVB light reducing the vitamin D production in the skin. People with dark 
pigmentation need substantially longer sun exposure compared to individuals with fair skin to 
synthesize the same amount of vitamin D (Armas 2007). Aging reduces vitamin D production 
in skin. The aging skin becomes thinner and the 7-dehydrocholesterol concentration in the 
epidermis decreases. This causes a reduced response to UVB light and a more than twofold 
decrease in the formation of previtamin D3 (MacLaughlin 1985). Vitamin D is fat soluble 
and is found in oily fish like salmon and herring. Cod liver oil is another excellent source of 
vitamin D. Mushrooms are good sources of vitamin D but only if they are exposed to UVB 
irradiation. Fortified dairy products also contain vitamin D. 
 
3.3. VITAMIN D AND CARDIOVASCULAR MORBIDITY -MECHANISMS 
 
The mechanism for how vitamin D can affect cardiovascular disease outcomes has not yet 
been completely elucidated. Two of the central proposed mechanisms are: 
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3.3.1 Suppression of the renin-angiotensin-system 
  
The renin–angiotensin system (RAS) plays a key role in regulating blood pressure and in 
controlling water and sodium balance. Elevated RAS activity is an important mechanism in 
the pathogenesis of hypertension. Inhibitors of RAS as angiotensin converting enzyme (ACE) 
inhibitors, angiotensin II receptor blockers (ARB), and renin inhibitors are therefore widely 
used in the clinic (Skov 2014). Studies have shown that 1,25-dihydroxyvitamin D3 can 
decrease renin and angiotensin II thereby reducing blood pressure. Vitamin D deficient 
individuals may also have an attenuated reduction in renal plasma flow in response to 
angiotensin II stimulus. This supports the thesis that vitamin D deficiency may be associated 
with an upregulated RAS (Forman 2010). 
 
3.3.2 Enhancing endothelial and vascular function 
    
The endothelium plays an important role in the maintenance of vascular homeostasis. 
Deficient endothelial function has been suggested to provide a final common pathway by 
which multiple risk factors exert their deleterious effects on cardiovascular health. In normal 
vascular physiology, nitric oxide (NO) plays a crucial role in maintaining vascular tone by 
silencing oxidative processes potentially harmful for the endothelium (Gimbrone 1999). 
VDRs and 1-alpha-hydroxylase that convert vitamin D to its active form are found in the 
vascular endothelium (Zehnder 2002). In vitro studies have shown that vitamin D interaction 
with VDR increases NO formation thereby reducing the oxidative stress in the endothelium 
(Molinari 2011). Vitamin D also induces VSMC proliferation (Cardús 2006). It has been 
hypothesized that this can reduce vascular calcification by reducing the space for apoptotic 
bodies that are inducers of vascular calcium deposition (Proudfoot 2000). Endothelial 
function can be assessed in vivo by measuring brachial artery flow-mediated dilation (FMD). 
Vitamin D deficiency may cause a reduced FMD and an increased arterial stiffness (Al 
Mheid 2011). Vitamin D has also been shown to have anti-inflammatory properties important 
for the endothelial function by regulating the production of various cytokines. In vitro, 
vitamin D can reduce the production of tumor necrosis factor α (TNF-α) and other pro 
inflammatory cytokines (Zhang 2012). 
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4 GENERAL AIMS 
 
 
 
1. To investigate if repeated intravitreal bevacizumab (IVB) injections every 6 weeks for 6 
months could improve visual acuity as compared to sham-treated control patients with ME 
secondary to CRVO and to evaluate the change in foveal thickness and the number of 
patients developing neovascular glaucoma in the study groups (paper I). 
 
2. To test if continuous injection every 6 weeks for 6 months could maintain visual acuity and 
to elucidate the impact of delaying treatment for 6 months in patients with ME secondary to 
CRVO (paper II). 
  
3. To investigate the seasonality in CRVO onset and the yearly incidence of CRVO in 
Stockholm Sweden (paper III). 
 
4. To test the hypothesis that patients with CRVO have an increased risk of vitamin D 
deficiency compared to matched controls (paper IV). 
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5  MATERIAL AND METHODS 
 
5.1 PAPER I - II 
 
5.1.1 Inclusion/exclusion criteria 
 
The main inclusion and exclusion criteria are summarized in table 1. Study ΙI included 
patients that had completed study I.                                                                                             
 
Key Inclusion Criteria Key Exclusion Criteria
CRVO with a duration of 6 months or less CRVO with neovascularisation.
Best corrected visual acuity (BCVA) 
between 15-65 ETDRS letters (Snellen 
equivalent approximately 20/50 to 20/500).
Any previous treatment for CRVO.
Mean central subfield thickness ≥ 300μm 
as measured by OCT (Cirrus OCT)
Intraocular surgery during the previous 3 
months.
Vascular retinopathy of other causes.
Glaucoma with advanced visual field defect 
or uncontrolled ocular hypertension 
>25mmHg despite full therapy.
Myocardial infarction or stroke during the 
last 12 months.
CRVO= central retinal vein occlusion, ETDRS= Early Treatment Diabetic Retinopathy 
Study, OCT = Optical coherence tomography
 
Table 1: Main inclusion/exclusion criteria  
 
5.1.2 Method 
  
From April 2009 to December 2010 60 eyes of 60 patients with CRVO were consecutively 
enrolled. Study patients were randomized with equal probability to IVB injections (study 
group) or sham injections (control group).  At baseline and at each follow-up visit, BCVA 
was measured at a distance of 4 m (or at 1 m if needed) by a certified tester using an 
ETDRS chart. Gonioscopy was performed prior to dilation at all visits. After dilation, 
optical coherence tomography (OCT) images were obtained by a certified technician using 
the Zeiss Cirrus OCT machine (Carl Zeiss Meditec, Inc.,Dublin, Ca). In study Ι each patient 
received 4 injections (IVB or sham) every 6 weeks. The total follow–up period was 24 
weeks. Study patients were masked to the treatment given. Staff performing visual acuity 
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testing, OCT, fundus photographs and follow-up investigators were masked to treatment 
group. In study II both groups received 4 IVB injections every 6 weeks. The total follow–
up period was an additional 24 weeks. Primary outcome measure: The proportion of 
patients gaining 15 ETDRS letters (3 lines) or more at 6 months (study I) and 12 months 
(study 2). Secondary outcome measures: Change in BCVA, change in CRT as measured by 
OCT and the number of patients with neovascular glaucoma defined as increased IOP due 
to the forming of new vessels in the angle as diagnosed by gonioscopy. 
 
5.1.3 Statistical analysis 
 
For the power calculation we assumed that 35% of the patients treated with bevacizumab 
and 5% of the sham-treated patients would achieve the primary endpoint (gain of at least 15 
ETDRS letters). With a statistical power of 80% and the level of statistical significance set 
at p<0.05 we estimated that a minimum of 24 patients would be required in each group 
(MedCalc Software, Mariakerke, Belgium). For statistical analyses, the independent 
Student's t-test and the Fisher’s Exact Test (to compare differences in distributions between 
the groups) were used. 
   
5.2 PAPER III 
 
5.2.1 Inclusion/ exclusion criteria  
 
The study population consisted of 854 consecutive patients with CRVO visiting the St. Erik 
Eye Hospital between January 2008 and December 2013. Patients that presented with 
neovascular glaucoma or with an uncertain date of onset of symptoms (n=278) were 
excluded from the analysis of seasonal onset but were included in the incidence calculation. 
Thus 576 patients were included in the analysis of seasonal distribution. 
 
5.2.2 Method  
 
Using the hospitals database the month of disease presentation was recorded in patients 
with CRVO and International Statistical Classification of Diseases Tenth Revision (ICD-
10) code H34.8a. The seasons were divided accordingly: Winter from December to 
February, spring from March to May, summer from June through August and autumn from 
September until November.  
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5.2.3 Statistical analysis 
 
Chi-square test and cross tabulations were used to compare differences in distributions 
between the seasons.  
 
5.3 PAPER IV 
 
5.3.1 Inclusion/ exclusion criteria 
  
During the study period every new patient presenting with CRVO with a maximum 
duration of 3 months was offered to participate. The control patients were chosen randomly 
by Statistics Sweden and matched for age and gender.  
 
5.3.2 Method  
 
The study included 72 patients with CRVO and 144 controls recruited between December 
2012 and August 2014. All the patients underwent a blood sample measuring the 25(OH)D 
level. Every season 120 patients in the control group were invited to participate in the 
study. They received a letter with information of the study, informed consent form and 
details about the blood sampling procedure. Every season 36 controls were included in the 
study. Similarly 18 patients with a new CRVO were included in the study group each 
season. 
 
5.3.3 Statistical analysis 
 
The power calculation was based on a difference in the vitamin D serum concentration 
between the groups of 10 nmol/l. With a statistical power of 80% and the level of statistical 
significance set at P<0.05, we estimated that a minimum of 50-60 patients would be 
required in the study group (MedCalc Software, Mariakerke, Belgium). For statistical 
analyses, the independent Student t test was used for continuous variables. For categorical 
data Pearson's chi-squared test and Fisher's exact test were used. 
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6  RESULTS 
 
6.1 PAPER I 
 
6.1.1 Visual outcomes 
 
 After 24 weeks 18/30 (60.0%) patients in the IVB group had gained ≥15 letters compared 
with 6/30 (20.0%) patients in the control group (p=0.003). At the end of follow up patients 
in the IVB group improved 14.1 letters compared to a loss of 2.0 letters in the control group 
(p<0.01) (figure 6). An analysis of the impact of disease duration on visual outcome was 
done. Patients with a disease duration of less than 90 days improved 18.3 letters (p<0.001) 
compared with patients with disease duration of more than 90 days who gained 9.1 letters 
(p=0.039). 
  
6.1.2 Anatomical outcomes 
 
The IVB group had a significantly greater reduction of the CRT (426 μm) than in the 
control group (102 μm) at all-time points up to week 24 (p<0.001) (figure 7). No ME, 
defined as CRT of less than 300μm at 24 weeks, was found in 26/30 (86.7%) patients in the 
treatment group as compared with 6/30 (20%) patients in the control group (p<0.001). 
 
6.1.3 Neovascularization 
 
No patients developed retinal neovascularization. At week 24 5/30 (16,7%) of the patients 
in the sham group had developed iris rubeosis. No patients in the IVB group had iris 
rubeosis at week 24 (p=0.052). 
 
6.2 PAPER II 
 
6.2.1 Visual outcomes 
 
At the end of follow up, 18/30 (60.0%) patients in the original IVB group had gained ≥15 
letters compared with 10/30 (33.3%) patients in the original sham group (p<0.05). In the 
original IVB group a further gain of 2.0 letters was seen with the fixed injection schedule 
during week 24 to 48. The original sham group, improved to a vision gain of 4.6 letters at 
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week 48 (p<0.05) (figure 6). A retrospective analysis of the impact of age and response to 
therapy was done. Younger patients had a better visual outcome. Overall patients <70 years 
improved 14.2 letters (95% confidence interval (CI), 6.3-22.0) compared with 7.4 letters 
(95% CI, 0.2-14.6) in the age group >70 years (p>0.05). Patients >70 years had a 
significantly worse outcome when receiving delayed treatment losing 1.4 letters (95% CI, -
9.7-8.4) in the original sham group compared with a gain of 20.1 letters (95% CI, 13.9-
26.3) the original IVB group (p=0.003). 
 
               
Figure 6. Mean change from baseline BCVA over time to month 12. Grey line represent 
original sham group and black line original IVB group. 
 
6.2.2 Anatomical Outcomes 
 
At 48 weeks the mean change in CRT was similar in both groups with a mean decrease of 
435 μm (original IVB group) and 404 µm (original sham group) at week 48 (p>0.05, Figure 
7). 
                 
Figure 7. Mean change from baseline CRT over time to month 12. Grey line represent 
original sham group and black line original IVB group. 
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6.2.3 Neovascularization 
 
No new cases of neovascularization were seen between week 24 and 48 in either group. 
 
6.2.4 Ocular safety and systemic adverse events (study I-II) 
  
There were no events of endophthalmitis, retinal tear or retinal detachment during the 48 
weeks treatment period. No serious non-ocular adverse events were reported. These studies 
were not powered to provide definite data on safety. 
 
6.3 PAPER III 
 
6.3.1 Seasonality of CRVO onset 
 
Every year during the 6 year study most patients had a CRVO onset during the winter-
spring period that was significantly higher than during the other seasons reaching its lowest 
levels in autumn. The number of patients presenting in the different seasons were 166 
(28.8% CI 95% 25.3-32.6) in winter, 172 (29.9% CI 95% 26.3-33.7) in spring, 131 (22.7% 
CI 95% 19.5-26.3) in summer and 107 (18.9% CI 95% 15.6-22.0) in autumn (p<0.0002 
winter/spring compared with summer/ autumn) (figure 8). There was an increased risk of 
over 40 % of developing CRVO in winter/spring compared with summer/ autumn. Odds 
Ratio (OR) 1.4 (95% CI 1.20-1.68). 
 
                                  
 
Figure 8. Overall central retinal vein occlusion onset (%) according to season. 
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6.3.2 CRVO incidence 
 
During the study period 854 subjects developed CRVO for an annual incidence of 2/10000 
for persons aged over 40 years. The annual incidence was increasing from 0.25/10000 at 45 
years of age up to 7/10000 above 80 (figure 9). Age was significantly associated with the 
incidence of CRVO (p<0.001). 
                         
                                      
 
 
Figure 9: Yearly incidence of central retinal vein occlusion (CRVO) stratified in age 
groups.  
 
 
6.4 PAPER IV 
 
6.4.1 Vitamin D deficiency 
 
A total of 216 patients were included in the study. Eight patients did not have eligible blood 
samples. Thus the final analysis included 208 subjects (68 patients in the study group and 
140 controls).   
     More than half the patients 35/68 (51.4%) in the CRVO group had vitamin D deficiency 
(serum 25(OH)D <50 nmol/l) compared to 55/140 (39.3%) in the control group. OR 1.64, 
(95% CI 0.91-2.94, p=0.10). The mean concentration of serum 25(OH)D was 55.3 nmol/L 
(95% CI 48.4-62.2) in the study group compared to 59.8 nmol/L (95% CI 55.4-64.2) in the 
control group (p=0.28). There was a significant seasonal variation of the serum 25(OH)D 
levels in both groups peaking during summer (p=0.04) (figure 10). 
     An ad-hoc analysis of the impact of age on vitamin D levels was done. In the CRVO 
group of patients less than 75 years old 62.1% (23/37) had vitamin D deficiency compared 
to 43.2% (38/88) in the control group.  Among subjects less than 75 years old the 25(OH)D 
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levels were significantly lower in the CRVO group 47.8 nmol/l (95% CI 40.6-55.0) 
compared to the control group with 59.0 nmol/l (95% CI 53.6-64.4) (p=0.02). 
 
  
                            
 
 
Figure 10: Seasonal distribution of vitamin 25 (OH) D levels. 
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7  DISCUSSION 
 
7.1 PAPER I-II 
 
In study I it was shown for the first time in a randomized prospective study the superiority 
of IVB treatment compared to sham injections in CRVO. More than 60% of the patients 
improved more than 3 lines on the ETDRS chart compared to 20% in the control group. 
The results showed comparable results to randomized trials with ranibizumab and 
aflibercept. Neovascular glaucoma may be a devastating complication of CRVO with 
additional vision loss and patient suffering. We found that no patients with active IVB 
treatment developed neovascular glaucoma compared to 16% in the control group. This is 
very good news for patients with ischemic CRVO. However, it is important to consider that 
by injecting anti-VEGF we are changing the natural course of the disease. This may in turn 
delay the onset of neovascular complications, especially when anti-VEGF treatment is 
withdrawn. Disease duration seems to have a critical impact on visual outcome. Patients 
initially on a sham-regime in study I improved with IVB treatment after 24 weeks but 
significantly less than the original IVB group. Both the CRUISE study evaluating 
ranibizumab and the COPERNICUS study investigating aflibercept showed similar results 
(Campochiaro 2011, Boyer 2012). ME causes disorganization of the retinal cellular 
structure and may cause severe damage to the neural cells. Long-lasting edema may lead to 
irreversible macular damage, which cannot be restored solely by resolution of the ME. 
Therefore, early therapeutic intervention to reduce the ME is important to optimize the 
patients’ visual outcome. Bevacizumab is an off-label treatment but has a widespread use 
over the world mainly because its lower price compared to other anti-VEGF agents. 
Bevacizumab may be a good treatment option especially in resource-poor regions due to 
price issues. 
 
7.2 PAPER III 
 
We found an increased risk of over 40% in the onset of CRVO during winter/ spring as 
compared with summer/autumn in Stockholm. Similar findings have been seen in some 
previous reports (Lavin 1987, Ho 2008) while others failed to show a seasonal relationship 
(Hayreh 1992). Several casual mechanisms may be involved in the seasonal onset of 
CRVO. A cold temperature may increase blood viscosity by boosting fibrinogen levels and 
raising the platelet and blood red counts (Bull 1979, Keatinge 1984, Neild 1984). Several 
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studies have shown that blood pressure is higher during the winter (Marti-Soler 2014). This 
may be caused by peripheral blood vessel vasoconstriction and higher levels of 
catecholamine and vasopressin during winter (Gordon 1988, Wittert 1992, Radke 2007). 
Vitamin D has a marked seasonal variation with lower levels during the winter. In vitro 
studies have shown that vitamin D is important for the endothelial function by inducing NO 
formation and reducing oxidative stress (Gimbrone 1999). Vitamin D is also known to have 
a lowering effect on the blood pressure by decreasing serum levels of renin and angiotensin 
II (Forman 2010). In the current study we found a CRVO incidence of 2/10000. In previous 
studies the incidence of CRVO has been between 3.3-4/10000 (Klein 2000, Cugati 2006). 
The higher incidence in these studies may be explained by the inclusion of asymptomatic 
patients diagnosed by fundus photography. In our study only symptomatic patients actively 
seeking medical care were included.  Our symptomatic CRVO incidence could be useful 
when estimating the actual number of patients that will seek medical care every year. 
 
7.3 PAPER IV 
  
In this study we found that more than 50% of the patients with CRVO had deficient vitamin 
D levels. In the complete data set no significant differences in vitamin D levels were found 
between the study groups. A non-planned sub group analysis showed that patients younger 
than 75 years old with CRVO had significantly lower vitamin D levels compared to 
controls. This result should be interpreted with caution because of the ad-hoc design and the 
smaller subgroup size. Interestingly patients older than 75 years had better vitamin D status 
than younger subjects. This is somewhat surprising considering that older individuals are at 
risk for vitamin D deficiency due to reduced dietary intake and decreased synthesis. This 
could possibly be explained by the increased focus on vitamin D supplementation lately in 
the elderly. In the recent Nordic Nutrition Recommendations (5
th
 edition 2012) individuals 
over 75 years are recommended to take 800 international units (IU) vitamin D. This 
hypothesis is strengthen by the fact that significantly more patients in the CRVO group 
above 75 years old received vitamin D supplementation. Our study suggests that vitamin D 
deficiency is prevalent in patients with CRVO. If vitamin D deficiency is involved in the 
causal pathway of cardiovascular disease or the result of confounding bias has not yet been 
determined. We cannot exclude that we did not have the statistical power to show that 
vitamin D deficiency may increase the risk for CRVO. Thus, larger studies are needed to 
establish if vitamin D deficiency is a risk factor in developing CRVO. 
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8   MAIN CONCLUSIONS 
 
1. In treating ME in CRVO, IVB injections are superior to sham injections in 
improving visual and anatomical outcomes. 
 
2. Early treatment is important to optimize the visual outcome in CRVO patients. 
 
3. There is an increased risk in the onset of CRVO during winter/ spring as compared 
with summer/autumn in Stockholm. We found a CRVO incidence of 2/10000. 
 
4. More than half the CRVO patients had deficient vitamin D levels. Patients younger 
than 75 years old with CRVO had significantly lower vitamin D levels compared to 
controls. 
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9 FUTURE PERSPECTIVES 
 
Intravitreal injections have fundamentally changed the treatment and outcomes in patients 
with CRVO. Several different anti-VEGF molecules and steroid implants are available on 
the market but the optimal treatment has yet to be established. Future head-to-head trials 
could answer this question. Different treatment algorithms could also have an impact on the 
visual outcome. Traditionally patients with CRVO have been treated with an initial loading 
dose followed by a PRN (as needed) regimen. This allows frequent relapses of the ME 
which may deteriorate visual outcome. More proactive regimens such as treat-and-extend 
where the patient is treated at each visit with extending intervals as long as the macula is 
dry may improve the outcome in these patients. Different treatment algorithms should be 
evaluated in future prospective studies. 
     Today we are unfortunately not able to treat the basic pathology. None of the new 
intravitreal injections have any known effect on the occluded vessel. New treatment 
modalities directed at the site of occlusion could dramatically change the natural course of 
the disease and reduce the risk of chronicity which is a common problem today.  
     The diagnosis of CRVO is usually straightforward due to the distinct fundus appearance. 
The presenting clinical picture and visual acuity can be quite various. Sometimes a 
spontaneous recovery can be seen but usually the natural course is not favourable. The 
reason for this variation is unclear. It could be hypothesized that processes in the clot or 
various collateral blood flow may influence this heterogeneity. However little is known 
about the clot, the size of the occlusion and if some parts of the blood vessel lumen have a 
patent blood flow. Newer diagnostic imaging tools visualizing the site of occlusion could 
help us increase our knowledge of the pathogenesis of CRVO and the variable natural 
course in these patients. 
     The role of seasonality in CVD and RVO is intriguing.  A deeper understanding of the 
processes involved in the seasonal disease onset could help in preventing some future cases. 
     Vitamin D deficiency is a common problem that may have an influence on global health. 
Whether vitamin D deficiency is involved in the causal pathway of cardiovascular disease 
has not yet been firmly determined. Large randomized studies on vitamin D 
supplementation are needed to answer this question. 
     In the meantime we can rejoice in the thought that sunshine may be the easiest way to 
improve our physical and mental health. 
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10 SAMMANFATTNING PÅ SVENSKA 
 
Centralventrombos i näthinnan (CRVO) innebär att en blodpropp bildas i en ven som för 
blod ut från ögat. Blodcirkulationen försämras i näthinnan som svullnar av vätska och blod 
vilket kan leda till grav synnedsättning. Den försämrade blodcirkulationen orsakar syrebrist 
i näthinnan vilket leder till att olika tillväktfaktorer (VEGF) utsöndras. VEGF försvagar 
blodkärlens väggar och kan orsaka att en svullnad i gula fläcken uppstår. VEGF kan även 
orsaka att nya sjuka blodkärl bildas som kan orsaka grön starr med högt tryck. 
Fram till för några år sedan har det inte funnits någon behandling för denna sjukdom. 
Genom att injicera en antikropp till VEGF i glaskroppen kan man behandla svullnaden i 
gula fläcken samt minska risken för att patienten utvecklar grön starr. 
     I delarbete I undersökte vi hur behandling med tillväxthämmaren bevacizumab 
påverkade synskärpan, svullnaden i gula fläcken samt risken för uppkomst av grön starr. 
Patienter som lottades till aktiv behandling fick bevacizumab injektioner med 6 veckors 
intervall. Patienter i kontrollgruppen fick simulerade injektioner med 6 veckors intervall. 
Sammanlagt 60 patienter deltog i studien med 30 deltagare i varje grupp. Studien pågick i 
24 veckor. Resultaten visade att patienter som fick behandling med bevacizumab 
förbättrades nästan 3 rader på syntavlan jämfört med en liten synförsämring hos patienterna 
i kontrollgruppen. Svullnaden i gula fläcken försvann hos nästan alla som fick bevacizumab 
behandling till skillnad mot kontrollgruppen där svullnaden kvarstod i de flesta fallen. Inga 
patienter i bevacizumab gruppen utvecklade grön starr.  
     I delarbete II studerade vi hur effekten av fördröjd behandling påverkade synskärpan. 
Vi undersökte även om de goda synresultaten från delarbete I kvarstod. Alla 60 patienterna 
fick bevacizumab injektioner med 6 veckors intervall under 24 veckors tid. Patienterna i 
den ursprungliga bevacizumab gruppen hade fortsatt bra synskärpa. De patienterna som 
fick bevacizumab behandling med 24 veckors fördröjning förbättrade synen dock var deras 
synvinst 2 rader sämre än den ursprungliga bevacizumab gruppen. Båda grupperna hade 
likvärdiga förbättringar av svullnaden i gula fläcken. Inga patienter utvecklade grön starr. 
Dessa båda arbeten visar för första gången i en prospektiv studie att bevacizumab  
förbättrar synskärpan vid CRVO i jämförelse med naturalförloppet samt att tidig 
behandling är viktig för att få bästa möjliga synprognos. Risken för grön starr minskar med 
bevacizumab behandling. 
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Tidigare studier har visat att insjuknandet i hjärt och kärlsjukdomar ökar under 
vinterhalvåret. Enstaka arbeten har visat ett liknande mönster även vid CRVO. Orsaken till 
detta är inte klarlagt. Det har spekulerats i att detta kan bero på olika säsongsrelaterade 
faktorer som förändras beroende på årstid såsom blodtryck, temperatur, luftföroreningar, 
fysisk aktivitet samt vitamin D brist. Vitamin D erhålls från kost eller från solljus. Då de 
flesta födoämnen har låga vitamin D nivåer är den viktigaste källan ultraviolett ljus som 
stimulerar hudens produktion av vitamin D. För att vitamin D skall produceras måste solen 
stå högt över horisonten vilket endast sker i Stockholm mellan maj och augusti. Under 
vinterhalvåret kan därför vitamin D brist uppstå. Vitamin D har visats ha en viktig roll för 
blodkärlens funktion samt blodtrycket. Det är möjligt att låga vitamin D nivåer kan öka 
risken för tromboser. 
     I delarbete III utvärderade vi när på året patienter insjuknade i CRVO samt hur vanlig 
sjukdomen var. Vi undersökte 854 patienter med CRVO mellan 2008 – 2013. Under varje 
år insjuknade flest patienter under vintern samt våren. 2 nya fall per 10000 invånare 
registrerades i genomsnitt varje år. Äldre patienter hade en ökad risk att få CRVO. 
Detta är den första studien som undersöker säsongsvariationen samt incidensen av CRVO i 
Sverige. 
     I delarbete IV jämförde vi i en prospektiv studie vitamin D nivåerna hos CRVO 
patienter med slumpvis utvalda kontrollpatienter. Detta för att utvärdera om vitamin D brist 
kan vara en riskfaktor för insjuknandet i CRVO. Sammanlagt 216 patienter deltog i studien. 
Mer än hälften av CRVO patienterna hade vitamin D brist jämfört med en tredjedel i 
kontrollgruppen. Dessa skillnader var inte signifikanta när hela patientmaterialet 
analyserades dock hade patienter yngre än 75 år statistiskt lägre vitamin D nivåer. Större 
studier behövs för att säkert utvärdera om vitamin D brist är en riskfaktor för CRVO. 
Denna studie visar för första gången att vitamin D brist är vanligt hos CRVO patienter.  
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